Thank you for joining us. The webinar will begin momentarily at 10:00am.
Welcome and Announcements

• This is NOT being recorded
• We will answer questions at the end of each segment as time permits
• Submit questions via Zoom Q&A window
• Slides will be posted on ORA website following the meeting
Agenda

• Welcome & Announcements – *Marcia Smith*
• Updates from the Human Research Protection Program – *Kristin Craun*
• Foreign Engagement and Updates from Research Policy and Compliance – *Ann Pollack*
• Updates from the OCGA Grants Team – *Kathy Kawamura*
• New Systems Supporting Research Safety and Animal Welfare – *Jennifer Perkins*
• EFM’s PAMS Report of Expired Funds to be Closed – *Jennifer Iglesias*
• EFM Fiscal Closing – *Monida Hean*
• OCGA Overview of New Forms for Federal Grant Applications – *Cindy Gilbert*
• Questions and Discussion
OHRPP Updates

- COVID-19 SPFC & IRB review
- OHRPP Office Hours
- Learn at Lunch
- Human Research News
Part of the DGSOM & UCLA Health system

Purpose is to:
- Assess scientific priority
- Assess operational feasibility
- Centrally coordinate use of data/specimens

For details on SPFC review processes, please visit their website
A “yes” responses to question 3.0/section 1.1b in a webIRB application will trigger routing to the SPFC COVID-19 committee before IRB review:
3.0 *Is this a COVID-19 research proposal that falls under the following scope:

a. Access to the suspected and confirmed UCLA Health COVID-19 patients.
b. Access to the electronic medical record chart or data of those patients.
c. Access to the remnant or research biospecimen collection of those patients.
d. Planning any clinical research interventional trial (drug/device) for those patients.
e. COVID Population-based studies that overlap the UCLA Health population or UCLA healthcare workers.

- Yes
- No
• SPFC meets *frequently*

• There are SPFC subcommittees that review different types of proposals to expedite their review process

• The SPFC issues correspondence directly to investigators
  ➢ For questions about the SPFC review process or specific SPFC correspondence, please [contact the SPFC directly](#)
• Once the SPFC has completed their review or has determined an application falls outside of their purview, the application is routed to OHRPP for IRB review

COVID-19 Review: Completed

- The IRBs prioritize COVID-related submissions and has an accelerated review process when requested

➤ *if you have decided to not proceed* based on the feedback from SPFC, *please withdraw* the application in webIRB to allow the IRB to focus on urgent reviews of other protocols
OHRPP “Office Hours”

- OHRPP Quality Improvement Unit staff are hosting **half-hour open Q/A sessions every week** to answer your pressing IRB questions

- **Next sessions** (every week, alternating Tuesday mornings and Thursday afternoons):
  - Thursday, May 21, 2020 3pm
  - Tuesday, May 26, 2020 8:30am
These sessions are designed to help:

- Researchers and their staff unsure where to start with an IRB submission (either a new study or taking over on ongoing study)
- Researchers and their staff with questions about OHRPP guidance documents

These sessions are not suited for:

- Specific questions about an application submitted
  - Consult with the OHRPP staff assigned to your submission for assistance instead
“Learn at Lunch” Series

Next session:

“HIPAA, Experimental Participants Bill of Rights, and Consent: best practices to avoid common pitfalls in research”

May 27, 2020 noon-1pm

Via zoom - Registration required

Presenters:

- **Polina Eshkol**, Manager, UCLA Health Office of Compliance Services
- **Moore Rhys**, Asst. Director, OHRPP
To be the first to know when OHRPP releases guidance and other updates, please subscribe to Human Research News

To subscribe, visit [ORA news subscription](#)
Any Questions?

Contact Information

OHRPP Website
http://ora.research.ucla.edu/ohrpp

Kristin Craun, OHRPP Director
Phone: x33150
Email: kristin.craun@research.ucla.edu
RPC Announcements

May 2020

Ann Pollack
Associate Vice Chancellor - Research
Research Policy & Compliance
Conflict of Interest

- A rapid review process has been established for COVID research projects
- Monthly CIRC meetings are taking place on schedule via zoom

COI@research.ucla.edu
Export Control

- The Export Control team is conducting reviews and responding to inquiries per usual business practices

Export.Controls@research.ucla.edu
Cannabis and Hemp

- All cannabis and hemp-related inquiries are being reviewed per standard procedures

CannabisQuestions@research.ucla.edu
UCLA Foreign Engagement Website

- Launched in March 2020
- Provides guidance to UCLA community, especially faculty, engaged in international collaborations and scholarly activities

RPC@research.ucla.edu

https://rpc.research.ucla.edu/foreign-engagement/
UCLA Foreign Engagement Website

https://rpc.research.ucla.edu/foreign-engagement/

- Provides guidance to UCLA community, especially faculty, engaged in international collaborations and scholarly activities on:
  - Disclosures for research sponsors
  - Disclosures to UCLA Guidance documents and memos

RPC@research.ucla.edu
UCLA-NBER (National Bureau of Economic Research) Memorandum of Understanding


- UCLA economists who are also affiliates of NBER may seek prior approval to submit certain grants through NBER
- Negotiated a reliance agreement that permits NBER to serve as the IRB of record for research proposals submitted under the streamlined process

RPC@research.ucla.edu
Questions?

Ann Pollack, Associate Vice Chancellor-Research
apollack@research.ucla.edu

Claudia Modlin, Assistant Director
cmodlin@research.ucla.edu

General Inquiries
RPC@research.ucla.edu
Thank you
COVID-19 Grant Considerations

Has there been any effects on your research projects due to COVID-19?

Helpful Hints

◦ Evaluate your PI’s Portfolio

◦ Consistent Messaging to Sponsor
  ◦ Various Communications, Notifications, Requests
    ◦ Ex: Progress Report, Prior Approval Request, etc.

◦ Future Considerations???
  ◦ Supplemental Funding, No Cost Extension, etc.

◦ New Award Considerations
  ◦ Delayed Start Date
  ◦ Rebudget Request, Change in Personnel, Change in Scope
COVID-19 Grant Considerations

NIH Research Performance Progress Report (RPPR)

F.2 Actual or anticipated challenges or delays and actions or plans to resolve them

Describe challenges or delays encountered during the reporting period and actions or plans to resolve them.

Describe only significant challenges that may impede the research (e.g., accrual of patients, hiring of personnel, need for resources or research tools) and emphasize their resolution.

Nothing to Report

or describe challenges or delays and plans to resolve them below (NIH recommended length is up to 1 page. Limit is 8000 characters or approximately 3 pages.)

NOTHING TO REPORT

F.3 Significant changes to Human Subjects, Vertebrate Animals, Biohazards, and/or Select Agents

Describe significant deviations, unexpected outcomes, or changes in approved protocols for human subjects, vertebrate animals, biohazards, and/or select agents during this reporting period.
COVID-19 Grant Considerations

NIH Research Performance Progress Report (RPPR)

Other Areas for Consideration

B) Accomplishments

B.1.a Have the major goals changed since the initial competing award or previous report?  
(Yes) (No)

If yes, list the revised major goals below (NIH recommended length is up to 1 page. Limit is 8000 characters or approximately 3 pages.)

B.6 What do you plan to do during the next reporting period to accomplish the goals?

Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

- Discuss efforts to ensure that the approach is scientifically rigorous and results are robust and unbiased. Remember that significant changes in objectives and scope require prior approval of the agency (e.g., NIH Grants Policy Statement, 8.1.2.).

- Include any important modifications to the original plans. Provide a scientific justification for any changes involving research with human subjects or vertebrate animals. A detailed description of such changes must be provided under Changes.
COVID-19 Grant Considerations

NIH Research Performance Progress Report (RPPR)

Other Areas for Consideration

G) Special Reporting Requirements

G.1 Special Notice of Award Terms and Funding Opportunity Announcement Reporting Requirements

Address any special reporting requirements specified in the award terms and conditions in the Notice of Award (NoA) or Funding Opportunity Announcement (FOA).

G.9 Foreign Component

“Foreign component” is defined as significant scientific activity that was performed outside of the United States, either by the grantee or by a researcher employed by a foreign organization, whether or not grant funds were expended. The following grant-related activities are significant and must be reported:

- involvement of human subjects or research with live vertebrate animals;
- extensive foreign travel by awardee project staff to collect data, or conduct surveys or sampling activities; or
- any awardee activity that may have an impact on U.S. foreign policy.

Examples of other award-related activities that may be significant are:

- collaborations with investigators at a foreign site anticipated to result in co-authorship;
- use of facilities or instrumentation at a foreign site; or
- receipt of financial support or resources from a foreign entity.

Foreign travel for consultation does not meet the definition of foreign component.
NIH- Foreign Component

NIH Foreign Component Definition

The performance of any significant scientific element or segment of a project outside of the United States, either by the recipient or by a researcher employed by a foreign organization, whether or not grant funds are expended. Activities that would meet this definition include, but are not limited to, (1) the involvement of human subjects or animals, (2) extensive foreign travel by recipient project staff for the purpose of data collection, surveying, sampling, and similar activities, or (3) any activity of the recipient that may have an impact on U.S. foreign policy through involvement in the affairs or environment of a foreign country. Examples of other grant-related activities that may be significant are:

- collaborations with investigators at a foreign site anticipated to result in co-authorship;
- use of facilities or instrumentation at a foreign site; or
- receipt of financial support or resources from a foreign entity.

Foreign travel for consultation is not considered a foreign component.

REMINDER: Prior Approval is REQUIRED per NIH Grants Policy Statement 8.1.2.10
LOCAL RESOURCES: UCLA Research Policy & Compliance Foreign Engagement
COVID-19 Information for NIH Applicants and Recipients of NIH Funding

- $1.532 billion for NIAID
- $103.4 million for NHLBI
- $60 million for NIBIB
- $36 million for NCATS
- $30 million for the NIH Office of Director
- $10 million for NIEHS
- $10 million for NLM

Emergency Competitive Revisions (PA-20-135)
Urgent Competitive Revision (PA-18-935)

Additional Video Links
- Proposal Submission & Award Management
- Human Subject & Clinical Trials
- Animal Welfare
- Peer Review

Notices of Special Interest (NOSIs) YouTube
NIH COVID History Update
NIH COVID-19 Grant Flexibilities

NIH COVID-19 Frequently Asked Questions

V. Foreign Components

1. If a post-doc on an active NIH grant must return home to a foreign country and work remotely due to COVID-19, must this be reported to NIH as a foreign component?

Yes, this would qualify as a foreign component as per the NIH Grants Policy Statement Section 1.2- Definition of Terms, which defines a foreign component as "the performance of any significant scientific element or segment of a project outside of the United States, either by the recipient or by a researcher employed by a foreign organization, whether or not grant funds are expended."
NIH Early Stage Investigators Status (ESI) NOT-OD-18-235

- Must include
  - eCommons Username
  - Number of Months for Extension
  - New ESI End Date
  - Justification for Extension Request

- Family Care Responsibilities
- Extended Periods of Clinical Training
- Extended Periods of Additional (non-degree) Research Training
- Disability or Illness
- Active Duty Military Service
- Clinical Loan Repayment Requirements
- Natural or Other Disaster

3. Will University closings due to COVID 19 be allowed as a reason for ESI end date extensions?

Yes, investigators that have been affected by COVID-19 (e.g. university closure) may submit requests for an extension of ESI status through eRA Commons via the ESI Extension request button in the Education section of their Personal Profile. Refer to the ESI FAQs and eRA Online Help for more information on how to request an extension of ESI status.
NSF Coronavirus Information

NSF COVID-19 Flexibilities

8. **Prior approval requirement waivers.** (2 CFR § 200.407)

12. **Extension of closeout.** (2 CFR § 200.343)

NSF has automatically extended the due date for submission of all final project reports and Project Outcomes Reports due between March 1 and April 30, 2020, by 30 days. These final reports must continue to be submitted via Research.gov. Recipients are reminded that NSF cannot make any new award or supplement any existing award if the PI or any co-PI(s)s has an overdue final report; therefore, it is vital that final reports be submitted by the revised due date.

NSF also has automatically extended the closeout period for awards that ended between November 30, 2019 and April 30, 2020 to 180 days.

The above requests for prior approval must be submitted via Research.gov. All other prior approvals specified in the applicable Prior Approval Matrix are waived. Recipients are reminded that they are to ensure that all costs charged to NSF awards must be consistent with Federal cost policy guidelines and the terms of the award, except as specified in this guidance.

NSF COVID-19 FAQs

NSF COVID-19 Deadline Extensions List
COVID-19 Grant Resources
American Heart Association (AHA)

- Proposal submission will transition to Proposal Central
  [AHA Application Information]

National Cancer Institute (NCI)

- Proposal Revised Minimum Levels of Effort
  [NOT-CA-20-047]

### Electronic Systems Challenges

- Cayuse
- NIH eCommons
- Grants.gov

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Role</th>
<th>Minimum Level of Effort in person months/year (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>R01/U01</td>
<td>Single PI</td>
<td>1.8 months (15%)</td>
</tr>
<tr>
<td></td>
<td>Multi-PI</td>
<td>1.2 months (10%) each</td>
</tr>
<tr>
<td>P01(^1)</td>
<td>Single PI</td>
<td>1.2 months (10%)(^2)</td>
</tr>
<tr>
<td></td>
<td>Multi-PI</td>
<td>0.96 months (8%) each</td>
</tr>
<tr>
<td></td>
<td>Project PI</td>
<td>1.8 months (15%)</td>
</tr>
<tr>
<td></td>
<td>Core Leader</td>
<td>0.6 months (5%)(^3)</td>
</tr>
<tr>
<td>R21</td>
<td>Single or Multi-PI</td>
<td>0.6 months (5%) each</td>
</tr>
</tbody>
</table>
Original, Signed (wet ink signature) Documents

Examples:

State of California – California Fair Political Practices Commission
  - 700U

National Institutes of Health (NIH)
  - Activation Form
  - Payback Agreement
THANK YOU !!!
Any Questions?

http://ocga.research.ucla.edu
Research Safety & Animal Welfare Administration (RSAWA) Updates

May 2020 RAF
RSAWA Updates

- System Updates
- AAALAC Site Visit
- RSAWA Contacts
**System Updates**

- New Research Application Tracking System (RATS)
  - User Training via Zoom [RATSHelp@research.ucla.edu](mailto:RATSHelp@research.ucla.edu)
    - Introduction to system
    - Advanced training
  - Launch date selected!
• **System Updates**
  ◦ SafetyNet – Radiation Use Authorization (RUA)
    ◦ Full launch
    ◦ Reviews already taking place
    ◦ User feedback = critical to improvements
• AAALAC Site Visit
  ◦ Animal program subject to triennial site visits
  ◦ Team of 4 council members and ad hoc consultants x 4 days
  ◦ Visit all animal facilities
  ◦ Review all records
  ◦ Interview leadership, ARC, researchers, DLAM, EH&S...
  ◦ Program description submitted April 14
  ◦ August visit?
• ARC Staff: arc@research.ucla.edu or 310-206-6308
• IBC Staff: ibc@research.ucla.edu or 310-794-0262
• RSC Staff: rsc@research.ucla.edu or 310-206-5601
• RSAWA Director: jperkins@research.ucla.edu or 310-794-9645
Extramural Fund Management

May 14, 2020
Agenda

• PAMS Report of Expired Funds to Close

• Fiscal Closing Update
PAMS Report of Expired Funds to Close

Jennifer Iglesias
PAMS Report of Expired Funds to Close

About the report

- This report includes contract and grant funds with a fund end date as of 120 days ago or earlier that are still open in the financial system.

- There are various reasons why funds cannot be closed, some requiring department and/or EFM to take action close these in the financial system.
  - Examples:
    - Final financial deliverables need to be submitted to the sponsor
    - Unallowable expenses need to be removed from funds
    - Outstanding A/R balances → UCLA is pending payment

A fund is closed when the OASIS fund table is updated to:

\[
\text{Fund Closed} = \text{"Y"} \quad \text{and} \quad \text{Reappropriate} = \text{"N"}
\]

We need your help to close expired funds!
# PAMS Report of Expired Funds to Close

## Data Elements

- The final financial deliverable for each fund with associated comments from PAMS

<table>
<thead>
<tr>
<th>Category</th>
<th>EFM Team</th>
<th>EFM Accountant</th>
<th>Department Fund Manager</th>
<th>Location Code</th>
<th>Fund Number</th>
<th>Fund End Date</th>
<th>Final Deliverable Due Date</th>
<th>Final Deliverable Status</th>
<th>Last Comment Date</th>
<th>LastComment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>Michelle Bright</td>
<td>Joe Bruin</td>
<td>4</td>
<td>12345</td>
<td>12/31/2019</td>
<td>03/30/2020</td>
<td>Submitted to Sponsor</td>
<td>03/24/2020</td>
<td>Submitted FFR to Sponsor via Commons.</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>Michelle Bright</td>
<td>Joe Bruin</td>
<td>4</td>
<td>67890</td>
<td>06/30/2014</td>
<td>08/30/2014</td>
<td>Submitted-Revised</td>
<td>01/21/2020</td>
<td>Revision Code: 01-To revise due to an increase in expenditures</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>Michelle Bright</td>
<td>Joe Bruin</td>
<td>4</td>
<td>14321</td>
<td>11/21/2019</td>
<td>02/21/2020</td>
<td>Submitted to Sponsor</td>
<td>02/21/2020</td>
<td>Submitted via ARA portal: Grants@Heart.</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>Olivia Williams</td>
<td>Joe Bruin</td>
<td>4</td>
<td>11345</td>
<td>05/31/2018</td>
<td>07/30/2018</td>
<td>Submitted to Sponsor</td>
<td>07/25/2018</td>
<td>Submitted via portal</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>Olivia Williams</td>
<td>Joe Bruin</td>
<td>4</td>
<td>68876</td>
<td>09/30/2019</td>
<td>11/30/2019</td>
<td>Submitted to Sponsor</td>
<td>11/18/2019</td>
<td>Submitted via e-mail.</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>Olivia Williams</td>
<td>Joe Bruin</td>
<td>4</td>
<td>23456</td>
<td>02/29/2019</td>
<td>03/31/2019</td>
<td>Submitted to Sponsor</td>
<td>03/28/2019</td>
<td>Invoice #5 (FINAL) emailed to sponsor, cc dept and PI.</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>Olivia Williams</td>
<td>Joe Bruin</td>
<td>4</td>
<td>98910</td>
<td>06/30/2019</td>
<td>08/31/2019</td>
<td>Submitted to Sponsor</td>
<td>08/26/2019</td>
<td>80189 06/302019F</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>Olivia Williams</td>
<td>Joe Bruin</td>
<td>4</td>
<td>34567</td>
<td>12/30/2019</td>
<td>02/28/2020</td>
<td>Submitted to Sponsor</td>
<td>01/24/2020</td>
<td>For internal closing only.</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>Olivia Williams</td>
<td>Joe Bruin</td>
<td>4</td>
<td>76543</td>
<td>02/28/2019</td>
<td>07/31/2019</td>
<td>Submitted to Sponsor</td>
<td>07/31/2019</td>
<td>Final FFR ended 1/31/19: Submitted via eRA Commons.</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>Olivia Williams</td>
<td>Joe Bruin</td>
<td>4</td>
<td>98675</td>
<td>08/31/2019</td>
<td>11/29/2019</td>
<td>Submitted to Sponsor</td>
<td>10/24/2019</td>
<td>J5 - 10/24/2019 - Submitted invoice to dept and PI.</td>
</tr>
</tbody>
</table>

- Financial information from general ledger as of the report run date, which include:
  - Inception-to-date Appropriation and Expenses, Operating Balance, Revenue, Accounts Receivable

<table>
<thead>
<tr>
<th>Fund Number</th>
<th>Fund End Date</th>
<th>Final Deliverable Due Date</th>
<th>Inception-to-date Appropriation</th>
<th>Inception-to-date Expenses</th>
<th>Total Operating Balance</th>
<th>Revenue</th>
<th>AR Balance</th>
<th>AP Balance</th>
</tr>
</thead>
<tbody>
<tr>
<td>12345</td>
<td>12/31/2019</td>
<td>03/30/2020</td>
<td>64,069.63</td>
<td>49,357.56</td>
<td>19,712.07</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>67890</td>
<td>06/30/2014</td>
<td>08/30/2014</td>
<td>250,792.89</td>
<td>250,792.89</td>
<td>250,893.72</td>
<td>201.66</td>
<td>250,893.72</td>
<td>-</td>
</tr>
<tr>
<td>14321</td>
<td>11/21/2019</td>
<td>02/21/2020</td>
<td>75,000.00</td>
<td>74,953.78</td>
<td>75,000.00</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11345</td>
<td>05/31/2018</td>
<td>07/30/2018</td>
<td>240,831.00</td>
<td>258,296.12</td>
<td>250,893.72</td>
<td>4622</td>
<td>250,893.72</td>
<td>-</td>
</tr>
<tr>
<td>68876</td>
<td>09/30/2019</td>
<td>11/30/2019</td>
<td>249,466.71</td>
<td>244,960.10</td>
<td>250,000.00</td>
<td>5,039.90</td>
<td>250,000.00</td>
<td>-</td>
</tr>
<tr>
<td>23456</td>
<td>02/28/2019</td>
<td>03/31/2019</td>
<td>226,924.00</td>
<td>226,868.61</td>
<td>226,924.00</td>
<td>55.39</td>
<td>55.39</td>
<td>226,924.00</td>
</tr>
<tr>
<td>98910</td>
<td>06/30/2019</td>
<td>08/31/2019</td>
<td>39,735.02</td>
<td>37,173.02</td>
<td>39,735.02</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>34567</td>
<td>12/31/2019</td>
<td>02/28/2020</td>
<td>235,979.29</td>
<td>237,690.01</td>
<td>235,979.29</td>
<td>1,710.72</td>
<td>235,979.29</td>
<td>-</td>
</tr>
<tr>
<td>76543</td>
<td>02/28/2019</td>
<td>07/31/2019</td>
<td>173,789.92</td>
<td>172,853.62</td>
<td>172,853.62</td>
<td>936.30</td>
<td>172,853.62</td>
<td>-</td>
</tr>
<tr>
<td>98675</td>
<td>08/31/2019</td>
<td>11/29/2019</td>
<td>19,588.98</td>
<td>19,588.98</td>
<td>19,588.98</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
## PAMS Report of Expired Funds to Close

### Data elements

<table>
<thead>
<tr>
<th>Completion Stage</th>
<th>Statuses in PAMS</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not Started</td>
<td>Not Started</td>
<td>Deliverable that has not yet been started. No action has been taken by EFM Preparer.</td>
</tr>
<tr>
<td>In Process</td>
<td>In Process</td>
<td>Deliverable currently in process for completion by EFM Preparer.</td>
</tr>
<tr>
<td></td>
<td>Pending Department Action</td>
<td>A deliverable that cannot be submitted to the sponsor until information is obtained from the department. Reasons for this can vary and will be noted within the comments of the financial deliverable (e.g. Milestone confirmation, invoice/financial report on sponsor template, etc.)</td>
</tr>
<tr>
<td></td>
<td>Submitted to Approver</td>
<td>Deliverable that has been completed by the EFM preparer and is pending EFM reviewer’s signature.</td>
</tr>
<tr>
<td></td>
<td>Approved</td>
<td>Deliverable that has been signed by the EFM reviewer.</td>
</tr>
<tr>
<td>Terminal</td>
<td>Completed</td>
<td>Indicates payment has been received or payment has been requested from the sponsor.</td>
</tr>
<tr>
<td></td>
<td>Submitted to Sponsor</td>
<td>A deliverable that has been completed and submitted to the sponsor.</td>
</tr>
<tr>
<td></td>
<td>Submitted-Revised</td>
<td>A deliverable that has been revised and submitted to the sponsor.</td>
</tr>
<tr>
<td></td>
<td>Reviewed Not Submitted</td>
<td>A deliverable not sent to the sponsor. Reasons for this can vary and will be noted via the comments of the financial deliverable.</td>
</tr>
</tbody>
</table>
When can a fund be fiscally closed?

- **Complete all financial deliverables**
  - All required invoices and/or financial reports are submitted to the sponsor

- **Confirm general ledger expenses agree with total expenses in the final invoice/financial report**
  - Complete cost transfers to/from the funds
  - Operating balance = $0

- **Confirm all obligations are paid**
  - Accounts payable balance = $0

- **Confirm all payments have been collected**
  - Accounts receivables balance = $0
PAMS Report of Expired Funds to Close

<table>
<thead>
<tr>
<th>Categories</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 All balances = $0</td>
<td>Balances in Operating Balance, Accounts Payable, and Accounts Receivable are zero.</td>
</tr>
<tr>
<td>2 Only open AR</td>
<td>Payment is owed to UCLA for the amount shown in the accounts receivable for that fund.</td>
</tr>
<tr>
<td>3 (Encumbrance or AP)</td>
<td>Balance in encumbrance: invoice has yet to be received or paid to the vendor. Balance in Accounts Payable: Vendor has not cashed a check payment.</td>
</tr>
<tr>
<td>4 Only non-Zero Operating Balance</td>
<td>The fund has a total operating balance.</td>
</tr>
<tr>
<td>5 Multiple balances</td>
<td>There are balances in various accounts of the fund.</td>
</tr>
<tr>
<td>6 Financial Deliverables in a Non-terminal status</td>
<td>Final financial deliverables for these funds have not been submitted to the sponsor.</td>
</tr>
</tbody>
</table>

- Pre-defined categories to guide departments with closing expired funds.
  - Note: categories are not exhaustive. Data can be organized to suit each department’s needs.

- Categories 1-5 are funds where invoice/financial reports have been completed.
- Category 1 are funds that EFM can independently close.
- Categories 2-6 is where department action is needed.
# Where to start?

<table>
<thead>
<tr>
<th>Categories</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 All balances = $0</td>
<td>Balances in Operating Balance, Accounts Payable, and Accounts Receivable are zero.</td>
</tr>
<tr>
<td>2 Only open AR</td>
<td>Payment is owed to UCLA for the amount shown in the accounts receivable for that fund.</td>
</tr>
<tr>
<td>Balance in one area only</td>
<td>Balance in encumbrance: invoice has yet to be received or paid to the vendor.</td>
</tr>
<tr>
<td>3 (Encumbrance or AP)</td>
<td>Balance in Accounts Payable: Vendor has not cashed a check payment.</td>
</tr>
<tr>
<td>4 Only non-Zero Operating Balance</td>
<td>The fund has a total operating balance.</td>
</tr>
<tr>
<td>5 Multiple balances</td>
<td>There are balances in various accounts of the fund.</td>
</tr>
<tr>
<td>Financial Deliverables in a Non-terminal status</td>
<td>Final financial deliverables for these funds have not been submitted to the sponsor.</td>
</tr>
</tbody>
</table>

## Category #2: Only open AR (EFM will involve department as needed)

## Category #6: Financial Deliverables in a Non-terminal status

- Deliverables with a status of “Pending department action”, complete information requested by EFM.
  - Detailed supporting schedules for invoices/financial reports on sponsor’s template
  - PI’s confirmation of milestone completion
  - PI’s assurance and justifications for awards subject to UCLA Policy 913: Disposition of Unexpended Balances in Fixed Rate and Fixed Price Contracts and Nonrefundable Grants
## Where to start?

<table>
<thead>
<tr>
<th>Categories</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 All balances = $0</td>
<td>Balances in Operating Balance, Accounts Payable, and Accounts Receivable are zero.</td>
</tr>
<tr>
<td>2 Only open AR</td>
<td>Payment is owed to UCLA for the amount shown in the accounts receivable for that fund.</td>
</tr>
<tr>
<td>3 (Encumbrance or AP)</td>
<td>Balance in encumbrance: invoice has yet to be received or paid to the vendor. Balance in Accounts Payable: Vendor has not cashed a check payment.</td>
</tr>
<tr>
<td>4 Only non-Zero Operating Balance</td>
<td>The fund has a total operating balance.</td>
</tr>
<tr>
<td>5 Multiple balances</td>
<td>There are balances in various accounts of the fund.</td>
</tr>
<tr>
<td>Financial Deliverables in a Non-6 terminal status</td>
<td>Final financial deliverables for these funds have not been submitted to the sponsor.</td>
</tr>
</tbody>
</table>

### Category #3: Balance in one area only (Encumbrance or AP)

- Financial deliverable has been submitted to the sponsor.
- Fund cannot be closed due to balance in either the encumbrance or accounts payable account.
- Review outstanding invoices from vendors and take appropriate action in BruinBuy.
## Where to start?

<table>
<thead>
<tr>
<th>Categories</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 All balances = $0</td>
<td>Balances in Operating Balance, Accounts Payable, and Accounts Receivable are zero.</td>
</tr>
<tr>
<td>2 Only open AR</td>
<td>Payment is owed to UCLA for the amount shown in the accounts receivable for that fund.</td>
</tr>
<tr>
<td>3 (Encumbrance or AP)</td>
<td>Balance in encumbrance: invoice has yet to be received or paid to the vendor. Balance in Accounts Payable: Vendor has not cashed a check payment.</td>
</tr>
<tr>
<td>4 Only non-Zero Operating Balance</td>
<td>The fund has a total operating balance.</td>
</tr>
<tr>
<td>5 Multiple balances</td>
<td>There are balances in various accounts of the fund.</td>
</tr>
<tr>
<td>Financial Deliverables in a Non-6 terminal status</td>
<td>Final financial deliverables for these funds have not been submitted to the sponsor.</td>
</tr>
</tbody>
</table>

**Category #4: Only non-Zero Operating Balance**

- Financial deliverable has been submitted to the sponsor. Fund cannot be closed due to the operating balance that exists.
- Review the total expenses reported in the final financial deliverable compared to total expenses recorded in the general ledger.
- Process cost transfers from/to the contract and grant fund.
Accessing the report

Post Award Management System (PAMS): https://pams.research.ucla.edu/

- Expired Funds to Close report is available to all PAMS users.
- Located under the “Reports” tab
- Report updated nightly, available on-demand via Excel download
- For access to PAMS, submit a New User Request form to: PAMSHelp@research.ucla.edu
Fiscal Closing Update

Monida Hean
Overview

- Fiscal Year End (FYE) closing is around the corner
- Corporate Financial Services (CFS) released the 2019-20 Closing Schedule for Fiscal Year End on 04/24/2020
- EFM have compiled deadlines for campus to submit to EFM for review and processing
- EFM sent an announcement of FYE Close EFM deadlines on 05/13/2020.
  - Email Subject: 2019-20 FYE Close - EFM Deadlines
What to do in May and continuing through FYE Close

- Review the fiscal closing letter and schedule to identify deadlines applicable to your area

- **Conduct monthly reconciliation and ledger review:**
  - Verify that expenses booked to the ledger have been recorded to the appropriate FAU
  - Process cost transfers for adjustments, if needed
  - Submit vendor and subcontractor invoices to Accounts Payable in a timely manner
  - Contact vendors and subcontractors for invoices billing for goods and services rendered during FY19-20
# FYE Close – EFM Deadlines

<table>
<thead>
<tr>
<th>Description</th>
<th>Deadline to Submit to EFM for Review/Processing</th>
<th>Deadline for EFM to Review, Approve, and Process</th>
</tr>
</thead>
<tbody>
<tr>
<td>Payroll (UCPath) Direct Retro Expense Transfer</td>
<td>06/30/2020 @ 10:00 AM</td>
<td>07/06/2020 @ 5:00 PM</td>
</tr>
<tr>
<td>PPS Costs Transfer Journal Request</td>
<td>06/30/2020 @ 10:00 AM</td>
<td>07/10/2020 @ 8:00 PM</td>
</tr>
<tr>
<td>Accrual/Deferral Forms and Supporting Documents</td>
<td>07/06/2020 @ 10:00 AM</td>
<td>07/10/2020 @ 8:00 PM</td>
</tr>
<tr>
<td>NPEAR Non-Payroll Expense Adjustments</td>
<td>07/06/2020 @ 10:00 AM</td>
<td>07/10/2020 @ 8:00 PM</td>
</tr>
</tbody>
</table>
Expense Transfer

Payroll and Non-Payroll

- If the expense transfers are submitted after the deadlines, there is no guarantee that it will be reviewed in time for the fiscal year.

- Expense transfers that are not reviewed will be reviewed and processed next fiscal year.
When accruals are required & why it matters:
- The Governmental Accounting Standards Board (GASB) requires the UC/UCLA financial statements to be prepared on an “accrual basis” where expenses incurred in a fiscal year are recorded to the year which goods and services were rendered.
- In other words, an accrual is required if a department receives an invoice for expenses that will be recorded to a research project after the AP deadline of June 12th.

Steps to submit an accrual:
- Complete the accrual Form E
- Complete journal justification
- Submit supporting documentation to EFM at EFMOperations@research.ucla.edu

Note: accrual forms, justification template, and instructions will be published by CFS in June
Any Questions?

Contact Information

EFM Website
http://efm.research.ucla.edu

Jennifer Iglesias
Phone: x42846
Email: jennifer.iglesias@research.ucla.edu

Monida Hean
Phone: x69479
Email: monida.hean@research.ucla.edu
OCGA Updates

Research Administration Forum
May 14, 2020
Today’s Topics

• NSF-approved formats for Biographical Sketch and Current and Pending Support
• NIH and AHRQ Forms-F
• OCGA Master Training
NSF Biosketch and Current and Pending Support

Format/System Requirements

• Required for all proposals submitted or due on or after June 1, 2020.

• Two options for Biosketch and Current and Pending Support:
  ▪ SciENcv
  ▪ Fillable PDF.

• SciENcv will produce an NSF-compliant PDF version of the Current and Pending Support information.
  ▪ Save the document to a local drive.
  ▪ Upload to proposal (FastLane, Research.gov, S2S Grants).
  ▪ Do not alter SciENcv-generated documents.
    ◦ NSF systems can detect altered documents and will generate an error.
What’s “New” – Current and Pending Support

• Information must be provided for all current and pending support regardless of whether it is received through UCLA or directly to the individual.

• Project or in-kind contributions without a commitment of time are not required to be reported.

• Examples expanded to include non-profit organizations.
NSF Biosketch and Current and Pending Support

What’s “New” – Biographical Sketch

• Appointments section must include all academic, professional or institutional titled positions regardless of whether payment is received.

• Synergistic Activities must be specific and cannot include multiple examples for a single activity.
NSF Biosketch and Current and Pending Support

Resources

• NSF
  ▪ NSF-Approved Formats for the Biographical Sketch
  ▪ NSF-Approved Formats for Current and Pending Support
  ▪ NSF-Approved Formats for the Biographical Sketch & Current and Pending Support Sections of Proposals - NSF Webinar (recorded April 9, 2020)
  ▪ NSF ERA Forum Webinar (May 14, 2020)

• Other
  ▪ ORCID – UCLA Library Research Guides
  ▪ Using SciENcv to Create Your Biosketch – NC State University Libraries
  ▪ ORCID – Connecting the Research Community – NCURA Webinar (recorded April 30, 2020)
NIH and AHRQ Forms-F

**NOT-OD-20-077**

- Applies to applications with *due dates* on or after May 25, 2020.
- Complete list of current Parent FOAs available at:
  
  https://grants.nih.gov/grants/guide/parent_announcements.htm

Not all Forms-E FOAs will be reissued.

If no reissue information is indicated:

- use the current Parent FOA, or
- advise PI to check with Program Manager.
### NIH and AHRQ Forms-F

#### Selecting the Correct form set in S2S Grants

<table>
<thead>
<tr>
<th>Opportunity Number</th>
<th>Title</th>
<th>Comp. ID</th>
<th>Comp. Title</th>
<th>Use for</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA-18-590</td>
<td>Change of Grantee Organization (Type 7 Parent Clin, $200k)</td>
<td>Forms-E-Type7-</td>
<td>Use for fellowships</td>
<td></td>
</tr>
<tr>
<td>PA-18-590</td>
<td>Change of Grantee Organization (Type 7 Parent Clin, $300k)</td>
<td>Forms-E-Type7-</td>
<td>Use for instruments</td>
<td></td>
</tr>
<tr>
<td>PA-18-590</td>
<td>Change of Grantee Organization (Type 7 Parent Clin, $400k)</td>
<td>Forms-E-Type7-</td>
<td>Use for research grants</td>
<td></td>
</tr>
<tr>
<td>PA-20-142</td>
<td>Ruth L. Kirschstein National Research Service Award (Type 1)</td>
<td>Forms-F</td>
<td>Use for due dates</td>
<td></td>
</tr>
<tr>
<td>PA-20-145</td>
<td>Innovations in HIV Prevention, Testing, Adherence and Retention</td>
<td>Forms-F</td>
<td>Use for due dates</td>
<td></td>
</tr>
<tr>
<td>RFA-CA-20-004</td>
<td>Research Answers to National Cancer Institute’s (NCI)</td>
<td>Forms-F</td>
<td>Use for due dates</td>
<td></td>
</tr>
</tbody>
</table>

---

**Image Description:**
- The image shows a screenshot of the S2S Grants system, focusing on opportunities for selecting the correct form set.
- The system displays various types of opportunities, each with a unique identification number and title, along with notes on their primary uses.

---

**Note:**
- The image contains a mix of text and graphical elements, primarily focusing on the selection of correct forms for different grant opportunities.
# NIH and AHRQ Forms-F

## Electronic Submission

### Opportunity Details
- **Opportunity**: Mechanisms of Alcohol-associated Cancers (R01)
- **Opportunity Number**: PA-17-220
- **Package ID**: PKG00259223
- **Competition ID**: FORMS-F
- **Competition Title**: Use for due dates on or after May 25, 2020
- **CFDA #**
- **CFDA Description**
- **Offering Agency**: National Institutes of Health
- **Agency Contact**: eRA Service Desk Monday to Friday 7 am to 8 pm ET [http://grants.nih.gov/support/](http://grants.nih.gov/support/)
NIH and AHRQ Forms-F

Resources

• How to Apply - Application Guide
• Grants Administration Take 10: NIH FORMS-F Application Forms Update video
• High-level Summary of Form Changes in FORMS-F Application Packages
• Annotated Form Set for NIH Grant Applications
• Do I Have the Right Form Version For My Application?
• Application Forms, Form Updates, and Choosing the Correct Forms FAQs
OCGA Master Training

**S2S Grants Basics**
- May 20, 2020
- 9:00 – 11:30 AM
- Zoom Webinar

**Budgets 101**
- June 17, 2020
- 9:30 – 11:30 AM
- TBD

Details and registration at:

[https://ocga.research.ucla.edu/training-calendar/](https://ocga.research.ucla.edu/training-calendar/)
Any Questions?